Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

17.36 

0.21 1.2%

as of Dec 06 '19

52 Week Range:

15.04 25.31


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Invenra, Inc., StemSynergy Therapeutics, Inc., and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Jan '09 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) -1.52
-2.09
0.02
1.61
0.72
-0.30
-0.33
0.11
0.81
3.05
growth rate 0.0% 100.0% 7,950.0% -55.3% -100.0% 0.0% 100.0% 636.4% 276.5%
Earnings BIT -140.84
-92.40
76.99
-147.54
-244.86
-216.66
-119.18
-26.71
166.98
439.96
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0% 163.5%
Avg.PE -3.80
-6.20
8.16
-5.50
-1.00
-1.00
-1.00
-1.00
53.29
10.07
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0% -81.1%
ROA -36.30
-26.22
20.08
-26.50
-39.98
-64.61
-51.41
-15.10
24.56
66.43
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0% 170.5%
ROE 285.80
40.40
83.50
-76.29
-134.98
82.22
87.77
growth rate -62.4% 106.7% -100.0% 0.0% 100.0% 6.8%
ROIC -27.11
-41.33
83.43
85.26
growth rate 0.0% 100.0% 2.2%
Cur. Ratio 1.11
0.92
2.48
5.29
3.03
0.97
3.42
1.74
4.21
8.50
growth rate -17.1% 169.6% 113.3% -42.7% -68.0% 252.6% -49.1% 142.0% 101.9%
Quick Ratio 1.04
0.84
2.43
5.07
2.80
0.86
3.30
1.71
4.07
8.27
growth rate -19.2% 189.3% 108.6% -44.8% -69.3% 283.7% -48.2% 138.0% 103.2%
Leverage 4.34
2.43
7.60
6.69
2.30
1.10
growth rate -44.0% 212.8% -4.2% -65.6% -52.2%
Balance Sheet Jan '09 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 0.00
0.00
30.19
2.75
3.94
4.88
5.18
40.44
81.19
178.83
growth rate -90.9% 43.3% 23.9% 6.2% 680.3% 100.8% 120.3%
Acct.Payable 41.05
47.13
70.22
6.41
6.40
6.57
9.58
10.90
growth rate 14.8% 49.0% -90.9% -0.2% 2.6% 45.9% 13.9%
Cur.Assets 230.00
183.50
228.82
432.54
266.61
167.24
178.67
469.00
484.87
897.02
growth rate -20.2% 24.7% 89.0% -38.4% -37.3% 6.8% 162.5% 3.4% 85.0%
Total Assets 343.40
360.80
393.26
721.10
503.29
323.27
332.34
595.74
655.29
1,422.29
growth rate 5.1% 9.0% 83.4% -30.2% -35.8% 2.8% 79.3% 10.0% 117.1%
Cash 86.80
97.40
74.26
182.32
116.19
80.40
141.63
151.69
183.16
314.78
growth rate 12.2% -23.8% 145.5% -36.3% -30.8% 76.2% 7.1% 20.8% 71.9%
Inventory 0.00
0.00
0.00
0.00
2.89
2.38
2.62
3.34
6.66
9.84
growth rate -17.6% 9.9% 27.6% 99.4% 47.8%
Cur.Liabilities 207.10
199.90
92.33
81.70
87.85
170.43
52.25
268.79
115.17
105.47
growth rate -3.5% -53.8% -11.5% 7.5% 94.0% -69.3% 414.4% -57.2% -8.4%
Liabilities 507.10
589.10
302.63
424.66
437.05
438.10
473.15
506.42
370.33
134.83
growth rate 16.2% -48.6% 40.3% 2.9% 0.2% 8.0% 7.0% -26.9% -63.6%
LT Debt 40.40
170.70
176.65
322.57
335.48
259.14
417.94
0.41
12.10
growth rate 322.5% 3.5% 82.6% 4.0% -22.8% 61.3% -96.9% 2,865.4%
Equity -56.98
-228.33
90.63
296.43
66.24
-114.83
-140.81
89.32
284.96
1,287.45
growth rate 0.0% 100.0% 227.1% -77.7% -100.0% 0.0% 100.0% 219.0% 351.8%
Common Shares 107.00
109.00
130.00
160.00
184.00
194.00
209.00
251.00
312.00
313.00
growth rate 1.9% 19.3% 23.1% 15.0% 5.4% 7.7% 20.1% 24.3% 0.3%
Cash Flow Statement Jan '09 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 5.90
1.60
0.99
2.72
2.17
0.47
0.45
1.70
21.14
33.30
growth rate -72.9% -38.1% 174.2% -20.1% -78.2% -5.7% 281.0% 1,141.5% 57.5%
Cash Dividends 0.00 0.00 0.00 0.00
growth rate
Cash From OA -9.68
-101.05
-159.23
-123.15
-235.41
-141.05
210.40
165.61
415.72
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -21.3% 151.0%
FCF per Share -0.19
-0.95
-0.88
-0.79
-1.05
-1.22
-0.78
0.36
0.61
1.01
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 69.4% 65.6%
Sale Purchase of Stock 193.55
205.63
1.50
77.20
157.13
27.51
22.42
growth rate 6.2% -99.3% 5,043.3% 103.5% -82.5% -18.5%
FCF -20.00
-103.00
-160.00
-126.00
-201.00
-236.00
-142.00
205.00
144.00
382.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -29.8% 165.3%
Income Statement Jan '09 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 151.80
185.00
289.64
47.45
31.34
25.11
37.17
191.45
452.48
853.83
growth rate 21.9% 56.6% -83.6% -34.0% -19.9% 48.0% 415.1% 136.3% 88.7%
Op.Income -121.90
-91.40
75.70
-147.65
-244.76
-216.66
-119.18
-26.71
166.98
439.96
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0% 163.5%
IBT -140.80
-92.40
76.99
-147.54
-244.86
-261.48
-161.69
-70.22
158.58
452.09
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0% 185.1%
Net Income -135.20
-92.30
75.70
-147.65
-244.76
-261.30
-161.74
-70.22
154.23
690.07
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0% 347.4%
EPS -1.26
-0.85
0.58
-0.92
-1.33
-1.34
-0.77
-0.28
0.49
2.21
growth rate 0.0% 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0% 351.0%
Gross Profit 151.80
185.00
289.64
47.45
30.22
23.27
34.48
185.40
438.51
828.58
growth rate 21.9% 56.6% -83.6% -36.3% -23.0% 48.2% 437.8% 136.5% 89.0%
R&D 234.70
210.70
156.84
128.88
178.76
189.10
96.35
95.97
112.17
182.26
growth rate -10.2% -25.6% -17.8% 38.7% 5.8% -49.1% -0.4% 16.9% 62.5%

Quarterly Statements

Item Name Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Earnings BIT 125.18
111.90
84.76
91.99
115.61
growth rate -10.6% -24.3% 8.5% 25.7%
Balance Sheet Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Acct.Receivable 129.12
178.83
122.36
109.93
183.59
growth rate 38.5% -31.6% -10.2% 67.0%
Acct.Payable 8.68
10.90
9.75
12.27
8.35
growth rate 25.6% -10.6% 25.9% -32.0%
Cur.Assets 786.96
897.02
946.30
957.25
972.11
growth rate 14.0% 5.5% 1.2% 1.6%
Total Assets 1,024.37
1,422.29
1,541.79
1,643.10
1,784.87
growth rate 38.9% 8.4% 6.6% 8.6%
Cash 353.62
314.78
373.94
369.79
242.32
growth rate -11.0% 18.8% -1.1% -34.5%
Inventory 10.43
9.84
10.14
12.35
13.37
growth rate -5.7% 3.1% 21.8% 8.2%
Cur.Liabilities 90.91
105.47
125.13
110.80
141.07
growth rate 16.0% 18.6% -11.5% 27.3%
Liabilities 108.40
134.83
156.77
154.47
181.15
growth rate 24.4% 16.3% -1.5% 17.3%
LT Debt 12.53
12.10
19.96
growth rate -3.4% 65.0%
Equity 915.97
1,287.45
1,385.02
1,488.63
1,603.72
growth rate 40.6% 7.6% 7.5% 7.7%
Common Shares 0.30
0.30
0.30
0.30
0.30
growth rate 0.3% 0.7% 0.3% 0.3%
Cash Flow Statement Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Capital Expenditures 15.22
2.89
2.31
1.21
2.06
growth rate -81.0% -20.3% -47.6% 70.3%
Cash Dividends
growth rate
Cash From OA 164.55
104.59
161.59
131.73
75.61
growth rate -36.4% 54.5% -18.5% -42.6%
Sale Purchase of Stock
growth rate
FCF 149.33
101.70
159.29
130.52
73.56
growth rate -31.9% 56.6% -18.1% -43.6%
Income Statement Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Sales 225.40
228.60
215.49
240.28
271.70
growth rate 1.4% -5.7% 11.5% 13.1%
Op.Income 125.18
111.90
84.76
91.99
115.61
growth rate -10.6% -24.3% 8.5% 25.7%
IBT 128.95
116.37
90.67
99.77
122.66
growth rate -9.8% -22.1% 10.0% 22.9%
Net Income 126.63
360.09
75.78
79.04
97.45
growth rate 184.4% -79.0% 4.3% 23.3%
EPS
growth rate
Gross Profit 218.04
221.55
208.19
232.74
264.17
growth rate 1.6% -6.0% 11.8% 13.5%
R&D 44.74
57.27
63.29
81.93
97.30
growth rate 28.0% 10.5% 29.5% 18.8%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A (88.77)

YOY Growth Grade:

E (30.88)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 8.44 8.88 17.95
EPS / Growth 0.0% 1.96 43.2%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 31.1% 47.7%
Future PE 0.00 14.78 40.62
Future EPS 1.96 29.25 96.84
Value Price
MOS %
0.00
-100.0%
106.83
515.4%
972.22
5,500.4%
MOS Price 0.00 53.41 486.11
IRT 8.88 4.17 3.42

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.